KEM Evang,klinkiken Essen -mitte-gg Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: KEM Evang,klinkiken Essen -mitte-gg Pharmaceutical Import Records from India — 2 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

KEM Evang,klinkiken Essen -mitte-gg — Pharmaceutical Importer Profile (2026) | 2 Products, $1.0M Trade | TransData Nexus

KEM Evang,klinkiken Essen -mitte-gg

Pharmaceutical Importer · Germany · Ayurvedic & Herbal Products Focus · $1.0M Total Trade · DGFT Verified

KEM Evang,klinkiken Essen -mitte-gg is a pharmaceutical importer based in Germany with a total trade value of $1.0M across 2 products in 1 therapeutic categories. Based on 45 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. KEM Evang,klinkiken Essen -mitte-gg sources from 1 verified Indian supplier, with Greenship Exports accounting for 100.0% of imports.

KEM Evang,klinkiken Essen -mitte-gg — Import Portfolio & Supplier Network

KEM Evang,klinkiken Essen -mitte-gg import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to KEM Evang,klinkiken Essen -mitte-gg?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Greenship Exports	$895.4K	63	100.0%

KEM Evang,klinkiken Essen -mitte-gg sources from 1 verified Indian supplier across 21 distinct formulations. The sourcing is highly concentrated — Greenship Exports accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does KEM Evang,klinkiken Essen -mitte-gg Import?

Formulation	Value	Ships
Balaswagandhadi tailam ( lut	$101.7K	3
Baladhathryadi tailam ( lut	$100.7K	3
Kshirabalatailam ( lut	$100.6K	3
Dhanwantaram tailam ( lut	$98.7K	3
Thriphaladi tailam ( lut	$62.3K	3
Mahabala tailam ( lut	$60.1K	3
Murivenna ( lut -ad320422001371z	$60.1K	3
Valiya prasarani tailam ( lut	$58.0K	3
Himasagara tailam ( lut	$53.7K	3
Valiya narayana tailam ( lut	$49.4K	3
Ayyappalakera tailam ( lut	$32.2K	3
Karpasasthyadi tailam( lut	$30.1K	3
Kottamchukkadi tailam ( lut	$27.9K	3
Dhanvantaram mezhukupakam ( lut	$21.5K	3
Patoladi ghritam( lut	$8.6K	3

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Taila	Ayurvedic & Herbal Products	$987.5K	39	13.0%	2
2	Ghrita	Ayurvedic & Herbal Products	$17.2K	6	3.7%	2

KEM Evang,klinkiken Essen -mitte-gg imports 2 pharmaceutical products across 1 categories into Germany totaling $1.0M.

KEM Evang,klinkiken Essen -mitte-gg — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

KEM I Evang. Kliniken Essen-Mitte gGmbH, established in 1975, is a prominent healthcare provider in the Ruhr region of Germany. Operating three hospital sites in Essen—Evang. Huyssens-Stiftung, Evang. Krankenhaus Essen-Steele, and Evang. Krankenhaus Essen-Werden—the organization offers a comprehensive range of medical services across 22 specialized departments. With approximately 1,000 planned beds and a workforce of around 2,700 employees, KEM Essen-Mitte is recognized as a leading medical institution in the area.

The organization is structured as a non-profit limited liability company (gGmbH), reflecting its commitment to reinvesting resources into patient care and medical advancements. Its mission centers on providing patient care based on the latest scientific standards and the highest levels of medical and nursing quality. This dedication has earned KEM Essen-Mitte multiple accolades, underscoring its status among Germany's top clinics. (medi-karriere.de)

2Distribution Network

KEM I Evang. Kliniken Essen-Mitte gGmbH operates three hospital sites in Essen, Germany:

Evang. Huyssens-Stiftung: Located in Essen-Huttrop, this facility offers a range of medical services.

Evang. Krankenhaus Essen-Steele: Situated in Essen-Steele, it provides comprehensive healthcare services.

Evang. Krankenhaus Essen-Werden: Found in Essen-Werden, this hospital delivers various medical treatments.

While specific details about their logistics capabilities and geographic coverage beyond these locations are not publicly disclosed, the organization’s extensive network within Essen indicates a well-established distribution framework for medical supplies and pharmaceuticals.

3Industry Role

KEM I Evang. Kliniken Essen-Mitte gGmbH functions primarily as a hospital supplier within Germany's pharmaceutical supply chain. Its role involves sourcing and utilizing pharmaceutical products to support the medical treatments provided across its three hospital sites. The organization's focus on patient care and medical excellence underscores its commitment to maintaining a robust supply chain for pharmaceuticals.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — KEM Evang,klinkiken Essen -mitte-gg

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

KEM I Evang. Kliniken Essen-Mitte gGmbH's pharmaceutical imports from India are exclusively sourced from a single supplier, GREENSHIP EXPORTS, accounting for 100% of their Indian pharmaceutical imports. This indicates a high level of supplier concentration, which could pose risks such as supply chain disruptions or dependency on a single source. However, the consistent volume of shipments—63 in total—suggests a stable and reliable relationship between KEM Essen-Mitte and GREENSHIP EXPORTS. The total import value of $895K reflects a significant investment in these imports, highlighting the importance of this supplier to the organization's pharmaceutical procurement strategy.

2Supply Chain Resilience

The resilience of KEM I Evang. Kliniken Essen-Mitte gGmbH's supply chain is closely tied to its exclusive reliance on GREENSHIP EXPORTS for pharmaceutical imports from India. This single-source dependency may expose the organization to risks such as supply chain disruptions or changes in supplier reliability. The lack of publicly available information regarding backup suppliers or alternative sourcing strategies suggests a potential area for improvement in diversifying the supply chain to enhance resilience. Additionally, the diversity of formulations imported and the exposure to specific shipping routes are not detailed, making it challenging to fully assess the supply chain's robustness.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharma imports includes the Medicines Act (AMG), which sets forth requirements for the importation, distribution, and marketing of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from BfArM, ensuring that imported generics meet German standards for safety, efficacy, and quality. This process includes comprehensive documentation and compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceuticals in Germany necessitate that foreign manufacturers hold a valid GMP certificate recognized by the European Union, WHO, or PIC/S. Indian exporters must ensure that their manufacturing facilities comply with these standards to facilitate the importation of their products into Germany. Additionally, wholesalers must obtain authorization from the competent German authorities, which involves demonstrating compliance with regulatory requirements and maintaining appropriate storage and distribution conditions.

3Quality & Labeling

KEM Evang,klinkiken Essen -mitte-gg — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

KEM I Evang. Kliniken Essen-Mitte gGmbH's focus on Ayurvedic and herbal products, particularly Taila and Ghrita, indicates a strategic interest in alternative medicine therapies. The substantial import value of $987K for Taila suggests a strong market demand for these products within the hospital's patient population. This demand may be driven by patient preferences for natural and holistic treatment options, as well as the therapeutic benefits associated with Ayurvedic formulations.

2Sourcing Profile

The hospital's sourcing strategy emphasizes the procurement of finished pharmaceutical formulations, specifically Ayurvedic and herbal products, from India. This focus aligns with the hospital's commitment to offering diverse treatment options to its patients. India's established reputation in producing high-quality Ayurvedic products positions it as a key supplier for KEM Essen-Mitte's procurement needs.

3Market Positioning

Based on its product mix, KEM I Evang. Kliniken Essen-Mitte gGmbH serves the hospital segment of the German market. The organization's substantial importation of Ayurvedic and herbal products indicates a strategic positioning to cater to patients seeking alternative and complementary therapies within a hospital setting.

Seller's Guide — How to Become a Supplier to KEM Evang,klinkiken Essen -mitte-gg

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with KEM I Evang. Kliniken Essen-Mitte gGmbH, particularly in the Ayurvedic and herbal product categories. Diversifying the hospital's supplier base could mitigate risks associated with single-source dependency and introduce innovative products to meet patient demand. Indian exporters should focus on ensuring compliance with German regulatory standards and demonstrating the quality and efficacy of their products to establish successful partnerships.

2Requirements & Qualifications

Indian exporters aiming to supply KEM I Evang. Kliniken Essen-Mitte gGmbH must possess certifications such as EU GMP, WHO GMP, or PIC/S to meet import licensing requirements. Additionally, products must comply with German quality standards, including batch testing, stability, and labeling requirements. Understanding and adhering to these regulatory frameworks is essential for successful market entry.

3How to Approach

Frequently Asked Questions — KEM Evang,klinkiken Essen -mitte-gg

What products does KEM Evang,klinkiken Essen -mitte-gg import from India?

KEM Evang,klinkiken Essen -mitte-gg imports 2 pharmaceutical products across 1 categories. Top imports: Taila ($987.5K), Ghrita ($17.2K).

Who supplies pharmaceuticals to KEM Evang,klinkiken Essen -mitte-gg from India?

KEM Evang,klinkiken Essen -mitte-gg sources from 1 verified Indian suppliers. The primary supplier is Greenship Exports (100.0% of imports, $895.4K).

What is KEM Evang,klinkiken Essen -mitte-gg's total pharmaceutical import value?

KEM Evang,klinkiken Essen -mitte-gg's total pharmaceutical import value from India is $1.0M, based on 45 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does KEM Evang,klinkiken Essen -mitte-gg focus on?

KEM Evang,klinkiken Essen -mitte-gg imports across 1 categories. The largest: Ayurvedic & Herbal Products (100.0%).

Get Full KEM Evang,klinkiken Essen -mitte-gg Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.